Citadel Advisors’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-23,399
| Closed | -$4.03M | – | 15467 |
|
|
2021
Q3 | $4.03M | Buy |
23,399
+19,564
| +510% | +$2.56M | ﹤0.01% | 4730 |
|
|
2021
Q2 | $481K | Sell |
3,835
-114,943
| -97% | -$14.5M | ﹤0.01% | 10144 |
|
|
2021
Q1 | $16.1M | Sell |
118,778
-286,058
| -71% | -$37M | ﹤0.01% | 2257 |
|
|
2020
Q4 | $51.8M | Buy |
404,836
+381,052
| +1,602% | +$44.7M | 0.01% | 926 |
|
|
2020
Q3 | $2.68M | Sell |
23,784
-161,299
| -87% | -$16.1M | ﹤0.01% | 4183 |
|
|
2020
Q2 | $17.6M | Buy |
185,083
+144,019
| +351% | +$13.9M | 0.01% | 1618 |
|
|
2020
Q1 | $3.69M | Sell |
41,064
-652,319
| -94% | -$50.7M | ﹤0.01% | 3145 |
|
|
2019
Q4 | $36.8M | Sell |
693,383
-92,290
| -12% | -$4.21M | 0.02% | 983 |
|
|
2019
Q3 | $31M | Buy |
785,673
+473,019
| +151% | +$20.5M | 0.01% | 1093 |
|
|
2019
Q2 | $12.8M | Buy |
312,654
+176,511
| +130% | +$7.31M | 0.01% | 1882 |
|
|
2019
Q1 | $6.34M | Buy |
+136,143
| New | +$5.98M | ﹤0.01% | 2652 |
|
|
2018
Q4 | – | Sell |
-18,230
| Closed | -$911K | – | 10037 |
|
|
2018
Q3 | $1.04M | Sell |
18,230
-344,329
| -95% | -$16.9M | ﹤0.01% | 5464 |
|
|
2018
Q2 | $17.6M | Buy |
362,559
+202,044
| +126% | +$7.36M | 0.01% | 1410 |
|
|
2018
Q1 | $6.28M | Buy |
160,515
+75,696
| +89% | +$3.22M | ﹤0.01% | 2206 |
|
|
2017
Q4 | $3.6M | Sell |
84,819
-152,693
| -64% | -$5.73M | ﹤0.01% | 2872 |
|
|
2017
Q3 | $8.86M | Buy |
237,512
+182,963
| +335% | +$6.35M | 0.01% | 1709 |
|
|
2017
Q2 | $1.66M | Sell |
54,549
-100,522
| -65% | -$2.91M | ﹤0.01% | 3412 |
|
|
2017
Q1 | $4.1M | Sell |
155,071
-33,607
| -18% | -$886K | ﹤0.01% | 2249 |
|
|
2016
Q4 | $4.82M | Sell |
188,678
-121,895
| -39% | -$3.86M | ﹤0.01% | 2046 |
|
|
2016
Q3 | $11.2M | Buy |
310,573
+140,933
| +83% | +$4.67M | 0.01% | 1267 |
|
|
2016
Q2 | $5.76M | Buy |
169,640
+160,977
| +1,858% | +$5.23M | 0.01% | 1703 |
|
|
2016
Q1 | $229K | Sell |
8,663
-213,039
| -96% | -$6.2M | ﹤0.01% | 5459 |
|
|
2015
Q4 | $10.8M | Sell |
221,702
-91,613
| -29% | -$3.3M | 0.01% | 1221 |
|
|
2015
Q3 | $7.8M | Sell |
313,315
-74,123
| -19% | -$2.23M | 0.01% | 1535 |
|
|
2015
Q2 | $12.3M | Sell |
387,438
-97,062
| -20% | -$3.13M | 0.01% | 1336 |
|
|
2015
Q1 | $18.4M | Buy |
484,500
+91,832
| +23% | +$3.65M | 0.02% | 1024 |
|
|
2014
Q4 | $15.3M | Buy |
392,668
+47,257
| +14% | +$1.65M | 0.02% | 1118 |
|
|
2014
Q3 | $10.4M | Buy |
345,411
+339,540
| +5,783% | +$9.56M | 0.01% | 1334 |
|
|
2014
Q2 | $199K | Buy |
+5,871
| New | +$196K | ﹤0.01% | 5573 |
|
Citadel Advisors's XLRN Position: Q4 2021 in Review
Citadel Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 23,399 shares — an estimated $4.03M sold.
Citadel Advisors first reported a position in XLRN in Q2 2014 and held it in 29 quarters. The position peaked at $51.8M in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Citadel Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Citadel Advisors sold 23,399 Acceleron Pharma shares in Q4 2021, an estimated $4.03M.
- Citadel Advisors first reported a position in Acceleron Pharma in Q2 2014 and held it in 29 quarters.
- Citadel Advisors's Acceleron Pharma position peaked at $51.8M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.